Objective Interstitial lung disease (ILD) is one of the most serious complications of
rheumatoid arthritis (RA). In the present study, we aimed to assess the efficacy of abatacept …

Background Interstitial lung disease (ILD) is a serious complication that represents the
second leading cause of death in patients with rheumatoid arthritis (RA). Treatment of RA …

Background: Treatment of rheumatoid arthritis (RA)-related interstitial lung disease (ILD) is
challenging, and many conventional and biologic disease-modifying anti-rheumatic drugs …

Objective To assess the efficacy of abatacept (ABA) in RA patients with interstitial lung
disease (ILD)(RA-ILD). Methods This was an observational, multicentre study of RA-ILD …

Objective: To prospectively evaluate the safety and efficacy profile of abatacept in patients
with rheumatoid arthritis–associated interstitial lung disease (RA-ILD). Methods: We …

Rheumatoid arthritis (RA) is a generally progressive, systemic autoimmune condition
characterized by chronic erosive synovitis. Interstitial lung disease (ILD) is a common extra …

Objectives To analyze the effect of disease-modifying antirheumatic drugs (DMARDs) on the
outcome of interstitial lung disease secondary to rheumatoid arthritis (RA-ILD). Patients and …

Introduction Interstitial lung disease (ILD) is a common extra-articular condition in
rheumatoid arthritis (RA), but few studies have systematically investigated its incidence and …

Objectives To examine the effectiveness of Janus-kinase inhibitors (JAKis) or abatacept
(ABA) in patients with rheumatoid arthritis-interstitial lung disease (RA-ILD). Methods …

Objectives: Interstitial lung disease (ILD) is an important complication of rheumatoid arthritis
(RA) or its treatment, and is associated with substantially increased mortality. Reports have …